Curis LifesciencesNSE:CURIS -1.92%19 Operating Margin % is 17.54% as of Mar. 2026, which is 6% below its 10-year median of 18.65. GuruFocus rates NSE:CURIS with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 952 Drug Manufacturers companies, Curis Lifesciences ranks better than 77.1% on this metric.
The historical rank and industry rank for Curis Lifesciences's Operating Margin % or its related term are showing as below:
NSE:CURIS'
s Operating Margin % Range Over the Past 10 Years
Min: 7.31 Med: 18.65 Max: 23.19
Current: 17.54
NSE:CURIS's Operating Margin % is ranked better than 77.1% of 952
companies
in the Drug Manufacturers industry
Industry Median: 7.58
vs NSE:CURIS: 17.54
Curis Lifesciences's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Curis Lifesciences Operating Margin % Related Terms
Curis Lifesciences Operating Margin % Historical Data
* Premium members only.
The historical data trend for Curis Lifesciences's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curis Lifesciences Operating Margin % Chart
Curis Lifesciences Annual Data
Trend
Mar23
Mar24
Mar25
Mar26
Operating Margin %
7.31
23.19
19.76
17.54
Curis Lifesciences Semi-Annual Data
Mar23
Mar24
Mar25
Mar26
Operating Margin %
7.31
23.19
19.76
17.54
NSE:CURIS vs ZTS, UTHR: Operating Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Curis Lifesciences's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curis Lifesciences Operating Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Curis Lifesciences's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Curis Lifesciences's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Curis Lifesciences's Operating Margin % for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curis Lifesciences (NSE:CURIS) has a Operating Margin % of 17.54% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Curis Lifesciences and its competitors. This is near median its historical median of 18.65. Over the past decade, Curis Lifesciences' Operating Margin % has ranged from 7.31 to 23.19. According to the industry distribution chart, Curis Lifesciences ranks #218 out of 952 companies in the Drug Manufacturers industry, placing it in the top 22.9%.
Is Curis Lifesciences' Operating Margin % too high?
Curis Lifesciences' current Operating Margin % of 17.54% is near median its 10-year median of 18.65. Over the past 10 years, this metric has ranged from a low of 7.31 to a high of 23.19. The Drug Manufacturers industry median Operating Margin % is 7.58. Curis Lifesciences' value of 17.54% is 131.4% above this industry median. Based on the distribution chart, Curis Lifesciences ranks #218 out of 952 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Curis Lifesciences has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Curis Lifesciences' Operating Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Curis Lifesciences ranks #218 out of 952 companies for Operating Margin %. This places Curis Lifesciences in the top 23% of its industry — outperforming the majority of peers. The industry median Operating Margin % is 7.58. Curis Lifesciences' value of 17.54% is 131.4% above this benchmark. Historically, Curis Lifesciences' own Operating Margin % has ranged from 7.31 to 23.19 over the past decade. While the company's 10-year median is 18.65 vs. the industry median of 7.58, Curis Lifesciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.58, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Curis Lifesciences's current Operating Margin % of 17.54% is 131.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Curis Lifesciences and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curis Lifesciences's current Operating Margin % is 17.54%, which is near median its own 10-year median of 18.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curis Lifesciences stock overvalued right now?
Curis Lifesciences (NSE:CURIS) has a current Operating Margin % of 17.54%. The current Operating Margin % is 17.54%, which is near median its 10-year median of 18.65 and 131.4% above the Drug Manufacturers industry median of 7.58. Curis Lifesciences' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Curis Lifesciences (NSE:CURIS), the current Operating Margin % is 17.54% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Curis Lifesciences Ltd is in the business of manufacturing of pharmaceutical products. It specializes in the manufacturing of a wide range of pharmaceutical products such as Tablets, Capsules, External Preparations, Oral liquid, and Sterile Ophthalmic Ointments. The company's business verticals are: Loan License manufacturing, Contract Manufacturing, and Direct Export. The company derives revenue from the sale of its pharmaceutical products.
19GF Score
Get the complete analysis for NSE:CURIS
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CURIS has been successfully added to your 